What is Erste Group Bank’s Estimate for MRK FY2026 Earnings?

Merck & Co., Inc. (NYSE:MRK) – Analysts at Erste Group Bank lowered their FY2026 earnings estimates for shares of Merck & Co., Inc. in a research report issued to clients and investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $2.70 per share for the year, down from their previous forecast of $5.14. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $2.76 per share. Erste Group Bank also issued estimates for Merck & Co., Inc.’s FY2027 earnings at $9.52 EPS.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same period last year, the firm earned $2.22 EPS. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS.

Several other analysts have also commented on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. CICC Research began coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Finally, Guggenheim boosted their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $133.94.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $127.47 on Monday. The stock has a market capitalization of $314.83 billion, a price-to-earnings ratio of 35.91, a PEG ratio of 5.04 and a beta of 0.19. The stock has a 50-day moving average of $120.11 and a 200 day moving average of $117.01. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $131.74.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were issued a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Hedge Funds Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Somerset Trust Co raised its stake in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after buying an additional 81 shares in the last quarter. Stonebridge Financial Group LLC lifted its holdings in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after acquiring an additional 81 shares during the period. Lederer & Associates Investment Counsel CA boosted its position in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock valued at $1,234,000 after acquiring an additional 84 shares in the last quarter. Pine Haven Investment Counsel Inc boosted its position in shares of Merck & Co., Inc. by 0.6% during the 2nd quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock valued at $1,834,000 after acquiring an additional 86 shares in the last quarter. Finally, Chesapeake Wealth Management increased its stake in Merck & Co., Inc. by 0.6% in the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after acquiring an additional 87 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.